Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Wednesday, August 05, 2020
Sonoco ThermoSafe is building PharmaPortal, a vendor-neutral blockchain platform for use by pharmaceutical manufacturers and carriers.
read more
PharmaMar announced an agreement with Specialised Therapeutics Asia to market the marine-based anti-tumour compound of the company, lurbinectedin.
read more
PharmaMar reported to National Securities Market Commission that Chugai Pharmaceutical had exercised its right to terminate without cause the License, Development and Commercialization Agreement for Zepsyre in Japan entered on December 22nd, 2016.
read more
Tuesday, November 07, 2017
PharmaMar announced a licensing agreement with Boryung Pharm to commercialize the marine-derived anticancer drug Zepsyre, if approved, in South Korea.
read more
Tuesday, January 28, 2020
PharmaMar and Bionical Emas have announced the launch of an EAP for lurbinectedin to treat patients in the United States with relapsed SCLC, who are unable to enter clinical trials and there are no appropriate alternative treatments.
read more
PharmaMar has announced today the signing of a commercialization and distribution license agreement with Pint Pharma International for the marine-derived anticancer drug Aplidin.
read more
PharmaMar announced the signing of an agreement with Impilo Pharma, a part of Immedica Group, for the exclusive promotion and distribution of its antitumour compound, Yondelis.
read more
Wednesday, February 14, 2018
Seattle Genetics has received exclusive worldwide rights to certain PharmaMar proprietary molecules for the development, manufacture and commercialization of ADCs.
read more
It is my pleasure to announce to you that Pharmalucence has been acquired by Sun Pharmaceuticals
(www.sunpharma.com), a world leader in the development and marketing of generic drugs.
read more
Friday, December 13, 2013
Pharmalucence, Inc. (www.pharmalucence.com) today announced that it has entered into an agreement with Lantheus Medical Imaging, Inc. (www.lantheus.com) to serve as a contract manufacturer of DEFINITY® Vial for (Perflutren Lipid Microsphere) ...
read more
Wednesday, April 09, 2025
PharmaLogic Holdings Corp. will acquire a majority stake in Agilera Pharma AS from the Institute for Energy Technology (IFE) in Norway, marking a significant step forward in the company's strategy to create the first fully-integrated, global CDMO ...
read more
PharmaLogic Holdings Corp., a contract development and manufacturing organization (CDMO) and radiopharmacy solutions provider, announced the opeing of its radiopharmaceutical production and research facility in the Bronx, New York.
read more
Thursday, October 31, 2024
PharmaLogic Holdings Corp. announced the official opening of its radiopharmaceutical production and research facility in Los Angeles, California.
read more
PharmaLogic Holdings Corp. announced the company has appointed Etienne Montagut, currently serving as President, to the position of President and Chief Executive Officer, effective as of 1 June 2025.
read more
Monday, December 30, 2019
PharmaLink announced that it started Phase 1 of its expansion project in response to new contracts and increased demand for its reverse distribution services.
read more